Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELIXOPHYLLIN SR vs ELIXOMIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and antagonizing adenosine receptors. It also has anti-inflammatory effects by reducing eosinophil infiltration and cytokine release.
ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Off-label: Treatment of apnea of prematurity, bradycardia in preterm infants, and respiratory depression due to opioid overdose
Treatment of refractory epilepsy,Adjunctive therapy for complex partial seizures,Off-label: neuropathic pain management,Off-label: bipolar disorder maintenance
300-600 mg orally every 12 hours; extended-release tablets. Adjust based on serum theophylline concentrations (target 5-15 mcg/m L).
500 mg orally once daily with a full glass of water, regardless of meals.
Terminal elimination half-life: 7-9 hours in adults (nonsmokers). In smokers, hepatic clearance is increased, reducing half-life to 4-5 hours. In patients with hepatic cirrhosis, half-life may extend to 24 hours. In neonates, half-life is prolonged (20-30 hours).
Terminal elimination half-life is 12-15 hours in adults with normal renal function; extends to 24-36 hours in moderate renal impairment (Cr Cl 30-50 m L/min).
Hepatic via cytochrome P450 isoenzymes, primarily CYP1A2, with minor contributions from CYP2E1 and CYP3A4.
Primarily metabolized by CYP3A4 and CYP2C19 isoenzymes; undergoes glucuronidation via UGT1A4. Active metabolite: N-desethyl-ELIXOMIN.
Renal: approximately 90% of the dose is eliminated via hepatic metabolism (N-demethylation and hydroxylation), with about 10% excreted unchanged in urine. The primary metabolites are 1-methylxanthine, 1,3-dimethyluric acid, and 3-methylxanthine. Fecal excretion is negligible (<1%).
Renal elimination of unchanged drug accounts for 60-70% of clearance; biliary/fecal excretion accounts for 20-25%; the remainder is metabolized hepatically with inactive metabolites excreted renally.
Approximately 40% bound to albumin. Binding is reversible and concentration-independent.
98% bound to albumin and alpha-1-acid glycoprotein.
Apparent Vd: 0.3-0.7 L/kg. This reflects distribution throughout total body water, with slightly higher distribution in neonates (0.8-1.0 L/kg) due to lower protein binding. The Vd is relatively small, indicating limited tissue binding.
0.6-0.8 L/kg; distributes rapidly into total body water, with moderate tissue binding.
Oral (sustained-release): 96-100% relative to oral immediate-release formulations. The sustained-release formulation yields lower peak concentrations but similar AUC. Food may increase peak concentration slightly (by about 10%) but does not affect overall bioavailability.
Oral: 70-80% (due to first-pass metabolism); Intramuscular: 90-95%.
No specific GFR-based dose reduction required; monitor serum levels closely. Theophylline clearance may be decreased in patients with impaired renal function, necessitating dose individualization.
GFR > 60 m L/min: no adjustment; GFR 30-60 m L/min: 250 mg once daily; GFR 15-29 m L/min: 125 mg once daily; GFR < 15 m L/min or dialysis: not recommended.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 50-75%; Child-Pugh C: reduce dose by 75% or avoid use. These recommendations are based on decreased clearance; monitor serum levels.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% (250 mg once daily); Class C: not recommended.
Initial dose: 10-14 mg/kg/day orally divided every 12 hours; may increase gradually based on serum concentrations. Maximum: 16 mg/kg/day for children 1-9 years; 12 mg/kg/day for children 9-16 years. Use extended-release tablets only in children who can swallow tablets whole.
Weight ≥ 40 kg: 500 mg once daily; Weight 20-39 kg: 250 mg once daily; Weight < 20 kg: not established.
Lower initial doses recommended (e.g., 300 mg/day) due to reduced clearance; monitor serum theophylline concentrations closely. Avoid in patients with significant cardiac or hepatic impairment.
No specific dose adjustment except based on renal function. Monitor for increased risk of QT prolongation and electrolyte disturbances. Initial dose should be 250 mg once daily if Cr Cl < 60 m L/min.
None.
WARNING: Risk of suicidal thoughts and behaviors; monitor for worsening depression or emergence of suicidal ideation.
Consider dose adjustment in patients with hepatic impairment, cardiac dysfunction, or those on drugs that alter theophylline metabolism (e.g., cimetidine, fluoroquinolones, macrolides).,Monitor serum theophylline levels to avoid toxicity (therapeutic range: 10-20 mcg/m L).,Seizure, cardiac arrhythmias, and death can occur at high serum concentrations.,Use with caution in patients with peptic ulcer disease, seizures, or hypothyroidism.,Elderly patients and those with underlying cardiac disease are at increased risk of adverse effects.
Hepatotoxicity (monitor LFTs); hematologic effects (thrombocytopenia, neutropenia); severe dermatologic reactions (SJS/TEN); pancreatitis; hyperammonemia; somnolence and dizziness; withdrawal seizures upon abrupt discontinuation.
Hypersensitivity to theophylline or any component of the formulation,Use of fixed-dose combination products with ephedrine (due to increased risk of CNS stimulation and cardiac effects)
Absolute: Hypersensitivity to ELIXOMIN or any component; history of drug-induced liver injury; concomitant use with MAOIs. Relative: Hepatic impairment; renal insufficiency (Cr Cl <30 m L/min); pregnancy (teratogenic effects in animal studies).
Avoid large amounts of caffeine (coffee, tea, chocolate). Charcoal-grilled foods may decrease absorption. High-protein, low-carbohydrate diets may alter metabolism.
Grapefruit and grapefruit juice significantly increase ELIXOMIN plasma concentrations, increasing risk of toxicity. High-potassium foods (e.g., bananas, oranges, spinach) should be limited due to risk of hyperkalemia.
Theophylline crosses the placenta. First trimester: Limited data, but no major teratogenic effects reported in human studies; animal studies show no evidence of teratogenicity. Second and third trimesters: No known teratogenic risk; fetal serum levels approximate maternal levels. Use only if clearly needed.
ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second and third trimesters: Increased risk of spontaneous abortion, preterm delivery, and fetal growth restriction due to uteroplacental insufficiency.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.7. At maternal therapeutic doses, infant exposure is low (estimated 1-10% of maternal weight-adjusted dose), and adverse effects are rare. However, some infants may experience irritability or insomnia. Caution is advised in premature infants or those with impaired clearance.
Not recommended during breastfeeding. Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infant (e.g., nephrotoxicity, ototoxicity).
During pregnancy, theophylline clearance may decrease in the third trimester due to reduced hepatic metabolism, leading to increased serum concentrations. Dose adjustments may be necessary, guided by serum level monitoring. Postpartum, clearance returns to non-pregnant levels within 2-4 weeks, requiring further dose adjustment.
Due to increased glomerular filtration rate (GFR) in pregnancy, higher doses of ELIXOMIN may be required to achieve therapeutic drug levels. However, given teratogenicity, use is contraindicated; alternative therapy should be considered.
Monitor serum theophylline levels (therapeutic range 10-20 mcg/m L). Sustained-release formulation allows twice-daily dosing. Use with caution in patients with hepatic impairment, heart failure, or fever, as clearance is reduced. Caffeine may increase toxicity.
Monitor serum potassium levels closely; ELIXOMIN can cause life-threatening hyperkalemia especially in patients with renal impairment. Avoid concurrent use with potassium-sparing diuretics.
Swallow tablet whole; do not crush or chew.,Take doses 12 hours apart consistently with or without food.,Avoid caffeine-containing beverages and foods.,Report symptoms of toxicity: nausea, vomiting, insomnia, palpitations.,Do not change brand without consulting prescriber.
Do not consume grapefruit or grapefruit juice while taking ELIXOMIN.,Take with food to reduce gastrointestinal upset.,Report any muscle cramps, palpitations, or irregular heartbeat immediately.,Avoid potassium supplements and salt substitutes containing potassium.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELIXOPHYLLIN SR vs ELIXOMIN, answered by our medical review team.
ELIXOPHYLLIN SR is a Xanthine Bronchodilator that works by Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and antagonizing adenosine receptors. It also has anti-inflammatory effects by reducing eosinophil infiltration and cytokine release.. ELIXOMIN is a Xanthine Bronchodilator that works by ELIXOMIN binds to and inhibits the N-methyl-D-aspartate (NMDA) receptor, reducing excitatory neurotransmission. It also modulates gamma-aminobutyric acid (GABA) activity, enhancing inhibitory signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELIXOPHYLLIN SR and ELIXOMIN depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELIXOPHYLLIN SR is: 300-600 mg orally every 12 hours; extended-release tablets. Adjust based on serum theophylline concentrations (target 5-15 mcg/m L).. The standard adult dose of ELIXOMIN is: 500 mg orally once daily with a full glass of water, regardless of meals.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELIXOPHYLLIN SR and ELIXOMIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELIXOPHYLLIN SR is classified as Category C. Theophylline crosses the placenta. First trimester: Limited data, but no major teratogenic effects reported in human studies; animal studies show no evidence of teratogenicity. Sec. ELIXOMIN is classified as Category C. ELIXOMIN is contraindicated in pregnancy (Category X). First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies. Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.